Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

Symbio Pharmaceuticals Limited

(TSE/TYO:4582)

Select Model

Rating:37Underperform

Price Target:JPY 41.00▼(-6.82% Downside)

Action:reiterated

Date:10/16/26

This exceptionally low score is primarily driven by an existential financial crisis, including plunging revenues and unsustainable cash burn. The severe fundamental weakness is compounded by extreme bearish price trends and a deeply negative valuation, presenting critical risks regarding solvency and operational continuity.

Positive Factors

Specialty Pharma FocusConcentration in oncology and hematology gives SymBio a defined specialty-pharmaceutical positioning rather than a broad, undifferentiated portfolio. This focus can support targeted clinical development, regulatory expertise, and deeper commercial knowledge over the next several quarters.

Negative Factors

Revenue ContractionMulti-year revenue contraction signals weakening commercial performance rather than a single temporary fluctuation. Continued top-line pressure can reduce the resources available for clinical development and commercialization, making recovery in profitability and cash generation more difficult.

Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 2.43B
Dividend Yield: ―
Average Volume (3M): 661.88K
Price to Earnings (P/E): -0.5
Beta (1Y): 0.82
Revenue Growth: -30.58%
EPS Growth: 6.93%
Country: Japan
Employees: 91
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers...

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

The company is facing severe financial distress characterized by a catastrophic revenue collapse, deeply negative profit margins (-365%), aggressive cash burn, and the introduction of new debt against rapidly shrinking equity.

Income Statement

8Very Negative

Balance Sheet

22Negative

Cash Flow

5Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.13B	1.31B	2.45B	5.59B	10.01B	8.25B
Gross Profit	791.92M	947.34M	1.87B	4.41B	7.60B	5.80B
EBITDA	-5.99B	-4.60B	-3.78B	-714.00M	2.06B	1.11B
Net Income	-6.03B	-4.78B	-3.83B	-1.96B	1.18B	2.03B
Balance Sheet
Total Assets	1.91B	3.87B	4.97B	8.17B	17.43B	15.18B
Cash, Cash Equivalents and Short-Term Investments	977.18M	2.88B	3.96B	6.52B	6.28B	3.86B
Total Debt	832.50M	1.98B	0	0	0	0
Total Liabilities	2.49B	2.60B	770.77M	8.14B	8.92B	8.43B
Stockholders Equity	-582.85M	1.27B	4.20B	7.21B	8.51B	6.75B
Cash Flow
Free Cash Flow	0	-4.58B	-3.44B	-427.48M	1.57B	76.20M
Operating Cash Flow	0	-4.58B	-3.42B	-194.69M	1.61B	140.04M
Investing Cash Flow	0	-75.92M	-3.96M	-376.70M	-47.13M	-70.85M
Financing Cash Flow	0	3.62B	708.47M	680.16M	627.99M	-71.92M

Symbio Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price44.00

Price Trends

50DMA56.32Negative

100DMA63.26Negative

200DMA82.39Negative

Market Momentum

MACD-3.23Positive

RSI21.83Positive

STOCH10.32Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 44.00 is below the 20-day moving average (MA) of 50.80, below the 50-day MA of 56.32, and below the 200-day MA of 82.39, indicating a bearish trend. The MACD of -3.23 indicates Positive momentum. The RSI at 21.83 is Positive, neither overbought nor oversold. The STOCH value of 10.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4582 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4574	61Neutral	JPY 13.02B	18.99	―	1.27%	13.30%	66.38%
JP:4597	54Neutral	JPY 7.37B	-8.11	-53.67%	―	32.42%	61.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4539	47Neutral	JPY 5.47B	-44.12	―	3.30%	0.31%	-194.72%
JP:4512	45Neutral	JPY 10.52B	30.73	―	1.16%	25.89%	―
JP:4586	39Underperform	JPY 3.29B	-3.30	―	―	167.44%	49.38%
JP:4582	37Underperform	JPY 3.72B	-0.48	―	―	-30.58%	6.93%

* Healthcare Sector Average

Performance Comparison

JP:4582 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4582	Symbio Pharmaceuticals Limited	44.00	-71.00	-61.74%
JP:4597	Solasia Pharma KK	27.00	-5.00	-15.63%
JP:4512	Wakamoto Pharmaceutical Co., Ltd.	303.00	16.42	5.73%
JP:4539	Nippon Chemiphar Co., Ltd.	1515.00	-100.80	-6.24%
JP:4574	Taiko Pharmaceutical Co., Ltd.	260.00	-15.00	-5.45%
JP:4586	Medrx Co., Ltd.	47.00	-82.00	-63.57%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026

Oct 29, 2026

SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales dropping 25.6% year-on-year to ¥722 million and losses deepening as operating profit fell to a ¥4,870 million...

SymBio’s First-Half Loss Deepens as Equity Turns Negative

Aug 10, 2026

SymBio Pharmaceuticals reported a sharp decline in first-half 2026 net sales to ¥469 million, down 27.3% year on year, alongside a wider operating loss of ¥3.64 billion as the company remained in a loss-making phase. The firm’s financ...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026

Symbio Pharmaceuticals Limited AI Stock Analysis